Clinical and economic burden of achondroplasia in the United States: results from a retrospective, observational study
Individuals with achondroplasia are characterized by a higher comorbidity burden and substantially higher HCRU and related costs relative to matched controls. The results also suggest that despite high HCRU and costs, individuals with achondroplasia likely are not seen by providers early enough nor are they necessarily seen by appropriate specialists, indicating a need for improved care and disease management.
Authors
- Christine L. Baker (ORCID: https://orcid.org/0000-0001-7532-7399)
- Paulette Negron Ericksen (ORCID: https://orcid.org/0009-0006-1981-7311)
- Jane Loftus (ORCID: https://orcid.org/0000-0002-2374-8607)
- Michael P. Wajnrajch (ORCID: https://orcid.org/0000-0002-8211-9237)
- Nadia Merchant (ORCID: https://orcid.org/0000-0001-8775-6481)
- Alison Slade (ORCID: https://orcid.org/0009-0007-5853-9200)
- José Alvir
- José Cara
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Pfizer (Switzerland) (CH)
- New York University (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Orphanet Journal of Rare Diseases
- Published
- 2025-02-27
- DOI
- https://doi.org/10.1186/s13023-024-03268-w
- Citations
- 1
- Primary Topic
- Connective tissue disorders research
- Type
- article
- Field-Weighted Citation Impact
- 1.82